Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...
The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...
Amid a rapidly evolving landscape in the treatment of muscle-invasive bladder cancer (MIBC), new findings presented at the ...
A recent study explored the association between rectal spacer use and the US county-level prevalence of erectile dysfunction.
According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Opioid prescriptions in the emergency department linked to small increases in hospital admission and subsequent opioid prescription use ...
Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...
Burnout in US oncologists has increased over the past 10 years, according to results of 2 surveys. 1 Researchers compared results of a 2023 survey of 328 oncologists to results of a 2013 survey of ...
Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback